Abstract
Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, espe......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
